2007 |
Martin Watzl |
The New Paediatric Regulation in the EU - Development, Implications and Comparison with US Experiences in Paediatric Drug Development *** |
|
|
2007 |
Dr. Tong Zhang |
Audit Check List for Sterile Active Pharmaceutical Ingredients |
|
|
2007 |
Dr. Stefan Zwilling |
Monoclonal antibodies developed as anticancer drugs: EU clinical trial application with focus on IMPD requirements *** |
|
|
2006 |
Dr. Ursula Bonsmann |
Biowaivers Based on the BCS Only for Class I |
|
|
2006 |
Dr. Hans-Joachim Gamperl |
Drug Risk Management from an Industry Perspective - a Task for the Life Time of a Medicinal Product *** |
|
|
2006 |
Ellen Güttler |
Extended Role of Scientific Advice as a Consequence of the New Medicines Legislation in the EU including a Comparison to the Situation in the USA *** |
|
|
2006 |
Dr. Maria Hambrügge |
Effective drug regulation as a promoter for access to medicinal products in developing countries New initiatives within the legal framework in the EU and regulatory activities by WHO and regional regulatory harmonisation initiatives *** |
|
|
2006 |
Dr. Katrin Jahn |
Zulassung und Handel von Produkten der traditionellen chinesischen Medizin (TCM) in der Schweiz und in Europa unter besonderer Berücksichtigung von Österreich und Deutschland *** |
|
|
2006 |
Dr. Sibylle Kaiser |
Tissue engineered products Need and requirements for an appropriate harmonised EU regulatory framework *** |
|
|
2006 |
Dr. Cortina Kaletta |
Overview of the Regulatory Environment for Developing New Vaccines Including the Specific Smallpox Vaccine and Pandemic Influenza Virus Vaccines *** |
|
|
2006 |
Dr. Angelika Koch |
Möglichkeiten und Grenzen der Vermarktung von pflanzlichen Produkten |
|
|
2006 |
Dr. Manfred Kurz |
Registration of antibody based medicinal products *** |
|
|
2006 |
Dr. Katrin Mayer |
Maintenance / life cycle management of a MRP-product A case study *** |
|
|
2006 |
Dr. Roger Müller-Pfaff |
Einführung des Hämaphereseverfahrens in den Blutspendedienst der Bundeswehr *** |
|
|
2006 |
Gabriele Schäfer |
Regulatory assessment of registration processes for biosimilar products- Conditions to be fulfilled to use special registration procedures designed by different decision matrices *** |
|
|
2006 |
Dr. Astrid Weyermann |
Labelling requirements for investigational medicinal products in multinational studies: bureaucratic cost driver or added value? *** |
|
|
2006 |
Renzo Wolbold |
The regulatory environment and requirements for biological and biotechnology-derived medicinal products in Japan |
|
|
2005 |
Katrin Dürr |
Comparison of marketing authorisations procedures for biotechnological products in the European Union and in Switzerland *** |
|
|
2005 |
Dr. Susanne Gluding |
Chemical and Toxicological Qualification of Plastic Packaging Materials for Sterile Solutions *** |
|
|
2005 |
Dr. Rudolf Gmeinbauer |
Decentralised Procedure, Mutual Recognition Procedure and Readability of SPC, PL, Labelling |
|
|